<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867281</url>
  </required_header>
  <id_info>
    <org_study_id>92-01-119-20728</org_study_id>
    <nct_id>NCT01867281</nct_id>
  </id_info>
  <brief_title>The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases</brief_title>
  <official_title>The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rassoul Akram Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of aspirin desensitization on symptoms
      and immunologic profile of patients with aspirin-exacerbated respiratory diseases (AERD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in SNOT-22 scores from Baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline and 6 months after treatment, all participants will complete the SNOT-22 questionnaire. SNOT-22 is a validated disease specific questionnaire that assesses the health related quality of life patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in serum concentration of IL-10</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline and 6 months after treatment, serum level of IL-10 will be investigated for all participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in concentration of serum TGF-beta</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline and 6 months after treatment, serum level of TGF-beta will be investigated for all participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in concentration of serum IFN-gamma</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline and 6 months after treatment, serum level of IFN-gamma will be investigated for all participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lund Mackay score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For all participants, Lund Mackay will be scored by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma attacks</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of asthma attacks will be recorded for all participants over a 6-month follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medication needs</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Medication needs to relief respiratory symptoms will be recorded for all participants over a 6-month period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>FEV1 for all patients will be assessed using spirometery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Asthma, Aspirin-Induced</condition>
  <arm_group>
    <arm_group_label>Intervention: Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>Intervention: Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnose of aspirin-exacerbated respiratory disease

          -  History of physician diagnosed asthma.

          -  History of physiacian diagnosed chronic rhinosinositis with nasal polyps.

          -  Positive reaction to aspirin challenge test.

          -  Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in   baseline
             dose of oral glucocorticoids for at least 3 months, and no history of hospitalization
             or emergency room visits for asthma for at least the prior 6 months).

        Exclusion Criteria:

          -  Being smoker

          -  pregnancy

          -  Current breastfeeding

          -  History of bleeding diathesis

          -  History of transient ischemic attack or stroke, or diabetes.

          -  History of abnormal hepatic function

          -  Uncontrolled hypertension or use of beta blocker medication.

          -  History of gastrointestinal ulcers or gastrointestinal bleeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hossein Esmaeilzadeh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Nabavi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zahra Aryan, MD, MPH, student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Molecular Immunology Research Center, Tehran University of Medical Sciences.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010 Oct;126(4):738-44. doi: 10.1016/j.jaci.2010.06.036. Epub 2010 Aug 21.</citation>
    <PMID>20728206</PMID>
  </reference>
  <reference>
    <citation>White AA, Stevenson DD. Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment? J Allergy Clin Immunol. 2010 Oct;126(4):745-6. doi: 10.1016/j.jaci.2010.08.037.</citation>
    <PMID>20920763</PMID>
  </reference>
  <reference>
    <citation>Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, Keck T. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008 Sep;63(9):1228-34.</citation>
    <PMID>18699939</PMID>
  </reference>
  <reference>
    <citation>Menzies D, Nair A, Meldrum KT, Hopkinson P, Lipworth BJ. Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. J Allergy Clin Immunol. 2008 May;121(5):1184-1189.e4. doi: 10.1016/j.jaci.2008.01.009. Epub 2008 Mar 4.</citation>
    <PMID>18313127</PMID>
  </reference>
  <reference>
    <citation>Swierczynska M, Nizankowska-Mogilnicka E, Zarychta J, Gielicz A, Szczeklik A. Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol. 2003 Nov;112(5):995-1001.</citation>
    <PMID>14610494</PMID>
  </reference>
  <reference>
    <citation>Vaidyanathan S, Williamson PA, Lipworth BJ. Is a positive nasal lysine-aspirin challenge test associated with a more severe phenotype of chronic rhinosinusitis and asthma? Am J Rhinol Allergy. 2012 May-Jun;26(3):e89-93. doi: 10.2500/ajra.2012.26.3767.</citation>
    <PMID>22643934</PMID>
  </reference>
  <reference>
    <citation>Higashi N, Taniguchi M, Mita H, Yamaguchi H, Ono E, Akiyama K. Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int. 2012 Sep;61(3):393-403. doi: 10.2332/allergolint.11-RA-0403. Epub 2012 May 25. Review.</citation>
    <PMID>22627848</PMID>
  </reference>
  <reference>
    <citation>Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc. 2012 Mar-Apr;33(2):117-21. doi: 10.2500/aap.2012.33.3541. Review.</citation>
    <PMID>22525387</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>asthma</keyword>
  <keyword>Aspirin desensitization</keyword>
  <keyword>Aspirin induced asthma</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Respiratory Hypersensitivity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Asthma, Aspirin-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
